News

The FDA’s decision was based, in part, on review of both phase I and phase II clinical trials of AP23573 conducted by Ariad in refractory sarcoma patients, and

In the study, complete or partial responses in seven of 56 patients with metastatic melanoma showed durability ranging from four months to the longest still ongoing at over

Novartis will be responsible for further development of AD 237 both as monotherapy and in combination with QAB149, its once-daily, long-acting beta2 agonist currently in phase II clinical

The findings, from a comparative clinical study on the effects of smoking on the pharmacokinetics of Tarceva (erlotinib) in healthy (non-cancer patients) smokers and non-smokers, built upon observations

The companies had previously entered into an agreement in June 2003 to develop an initial prescription steroid product for the US using one of Dow’s patented drug delivery

The chimeric hybrid analgesics are an invention of Chimeracom’s chief science officer, Dr Richard Kream, and the patent covers composition of matter for, and methods of treating pain

The trial will assess the safety of the formulation of BLP25 Liposome Vaccine (L-BLP25) that the companies expect to use in an upcoming phase III study. This formulation

Peninsula’s lead product candidate, doripenem, is a broad-spectrum antibiotic and a new member of the carbapenem class of beta-lactam antibiotics. Peninsula is currently evaluating doripenem in six phase

The vaccine, based on Vical’s proprietary DNA delivery technology, was co-developed at the National Institute of Allergy and Infectious Diseases’ (NIAID) Vaccine Research Center (VRC) and at Vical.